Literature DB >> 2574481

Striatal dopamine receptor occupancy during and following withdrawal from neuroleptic treatment: correlative evaluation by positron emission tomography and plasma prolactin levels.

J C Baron1, J L Martinot, H Cambon, J P Boulenger, M F Poirier, V Caillard, J Blin, J D Huret, C Loc'h, B Maziere.   

Abstract

The percentage occupation of striatal dopamine D2 receptors has been evaluated in 25 patients using 76Br-bromospiperone positron emission tomography (PET) and prolactin plasma levels (PRL) during oral neuroleptic treatment (11 studies), 1-90 days following discontinuation of such treatment (16 studies), and 1-120 days after last intramuscular administration of depot neuroleptics (nine studies). The PET-estimated occupation was highly significantly correlated in a sigmoid-like fashion to the logarithm of the chlorpromazine-equivalent dose of oral neuroleptics (suggesting a strict dose-occupation relationship during oral neuroleptic treatment and supporting the D2-mediated hypothesis of neuroleptic action), while PRL was weakly related to daily dosage. Following withdrawal, return to normal receptor availability, as estimated by PET, occurred within 5-15 days (suggesting that protracted effects of neuroleptics after withdrawal are not due to sustained D2 receptor occupation), but PRL values fell even more rapidly. Efficient treatment with depot neuroleptics resulted in marked PET-estimated D2 receptor occupation, stable over the whole 4-week drug-administration interval, suggesting that longer intervals could be appropriate; PRL values bore no relationship to PET-estimated occupation, indicating variable intersubject tolerance to neuro-endocrine dopamine blockade. Overall, PET was much more sensitive than PRL to estimate striatal D2 receptor occupation in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2574481     DOI: 10.1007/bf00589893

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients.

Authors:  M Smith; A P Wolf; J D Brodie; C D Arnett; F Barouche; C Y Shiue; J S Fowler; J A Russell; R R MacGregor; A Wolkin
Journal:  Biol Psychiatry       Date:  1988-04-01       Impact factor: 13.382

2.  Plasma prolactin and fluphenazine concentrations in patients receiving fluphenazine decanoate: stability over injection intervals.

Authors:  T R Norman; P F Marriott; N M Kimber; G D Burrows
Journal:  Int Clin Psychopharmacol       Date:  1987-10       Impact factor: 1.659

3.  Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases.

Authors:  P Seeman; N H Bzowej; H C Guan; C Bergeron; G P Reynolds; E D Bird; P Riederer; K Jellinger; W W Tourtellotte
Journal:  Neuropsychopharmacology       Date:  1987-12       Impact factor: 7.853

Review 4.  Neuroleptics and neuroendocrine function.

Authors:  J W Gunnet; K E Moore
Journal:  Annu Rev Pharmacol Toxicol       Date:  1988       Impact factor: 13.820

5.  Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain.

Authors:  D F Wong; H N Wagner; R F Dannals; J M Links; J J Frost; H T Ravert; A A Wilson; A E Rosenbaum; A Gjedde; K H Douglass
Journal:  Science       Date:  1984-12-21       Impact factor: 47.728

6.  Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.

Authors:  A DeLean; P J Munson; D Rodbard
Journal:  Am J Physiol       Date:  1978-08

7.  Interaction of benzodiazepines with neuroleptics at central dopamine neurons.

Authors:  H H Keller; R Schaffner; W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976-07       Impact factor: 3.000

8.  77Br-p-bromospiperone: a ligand for in vivo labelling of dopamine receptors.

Authors:  F Owen; M Poulter; R D Mashal; T J Crow; N Veall; G D Zanelli
Journal:  Life Sci       Date:  1983-08-22       Impact factor: 5.037

9.  Age-correlated loss of dopaminergic binding sites in human basal ganglia.

Authors:  J A Severson; J Marcusson; B Winblad; C E Finch
Journal:  J Neurochem       Date:  1982-12       Impact factor: 5.372

10.  Prolonged antidopaminergic actions of single doses of butyrophenones in the rat.

Authors:  A Campbell; R J Baldessarini; M H Teicher; N S Kula
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

View more
  26 in total

1.  In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia.

Authors:  J L Martinot; M L Paillère-Martinot; M F Poirier; M H Dao-Castellana; C Loc'h; B Mazière
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 2.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

3.  A method to estimate in vivo D2 receptor occupancy by antipsychotic drugs.

Authors:  R A Roemer; E Richelson; C Shagass; L Leventhal
Journal:  J Psychiatry Neurosci       Date:  1996-11       Impact factor: 6.186

4.  The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

Authors:  C J Bench; A A Lammertsma; P M Grasby; R J Dolan; S J Warrington; M Boyce; K P Gunn; L Y Brannick; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

5.  Rebound insomnia after abrupt clozapine withdrawal.

Authors:  J Staedt; G Stoppe; G Hajak; E Ruther
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1996       Impact factor: 5.270

6.  Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics.

Authors:  I Maurer; H J Möller
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

7.  A cross-validation study on the relationship between central D2 receptor occupancy and serum perphenazine concentration.

Authors:  Mirjam Talvik; Anna-Lena Nordström; Niels-Erik Larsen; Aurelija Jucaite; Simon Cervenka; Christer Halldin; Lars Farde
Journal:  Psychopharmacology (Berl)       Date:  2004-03-06       Impact factor: 4.530

8.  Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome.

Authors:  R L Albin; R A Koeppe; K Wernette; W Zhuang; T Nichols; M R Kilbourn; K A Frey
Journal:  Neurology       Date:  2009-04-21       Impact factor: 9.910

Review 9.  Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.

Authors:  Peter M Haddad; Angelika Wieck
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Olanzapine treatment of adolescent rats alters adult reward behaviour and nucleus accumbens function.

Authors:  Monika Vinish; Ahmed Elnabawi; Jean A Milstein; Jesse S Burke; Jonathan K Kallevang; Kevin C Turek; Carien S Lansink; Istvan Merchenthaler; Aileen M Bailey; Bryan Kolb; Joseph F Cheer; Douglas O Frost
Journal:  Int J Neuropsychopharmacol       Date:  2013-01-25       Impact factor: 5.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.